Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
40.21
+0.66 (1.67%)
Oct 29, 2025, 1:27 PM EDT - Market open
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts that cover Arrowhead Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $47.75, which forecasts a 18.75% increase in the stock price over the next year. The lowest target is $17 and the highest is $80.
Price Target: $47.75 (+18.75%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Hold | 3 | 3 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 8 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +98.96% | Oct 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +98.96% | Sep 2, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +49.22% | Aug 11, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $40 → $38 | Buy | Maintains | $40 → $38 | -5.50% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +98.96% | May 20, 2025 |
Financial Forecast
Revenue This Year
759.46M
from 3.55M
Increased by 21,287.21%
Revenue Next Year
398.73M
from 759.46M
Decreased by -47.50%
EPS This Year
0.08
from -5.00
EPS Next Year
-2.92
from 0.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 969.2M | 679.1M | ||||
| Avg | 759.5M | 398.7M | ||||
| Low | 561.5M | 99.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 27,192.3% | -10.6% | ||||
| Avg | 21,287.2% | -47.5% | ||||
| Low | 15,713.6% | -86.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.97 | -0.87 | ||||
| Avg | 0.08 | -2.92 | ||||
| Low | -1.04 | -4.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.